Innovating Works

GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO

Activa
NAVIPP: New AntiVirals for Infections with Pandemic Potential EUROPEAN RESEARCH INFRASTRUCTURE ON HIGHLY PATHOGENIC AGENTS tramitó un HORIZON EUROPE: For infectious disease management and control, vaccines are considered golden countermeasures. but are not the most adequate tool for mitigating the early effects of an outbreak. Taking the recent COV...
2023-11-22 | Financiado
UNITE4TB: ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM tramitó un H2020: Current anti-tuberculosis (TB) drug regimens face serious limitations at times of increasing antimicrobial drug resistance. Fortunately, for the first time for centuries, several novel anti-TB compoun...
2021-06-01 | Financiado
ERA4TB: EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS UNIVERSIDAD CARLOS III DE MADRID tramitó un H2020: The European Regimen Accelerator for Tuberculosis (ERA4TB) has the explicit goal of developing a new combination therapy to treat all forms of TB starting from ~20 leads and drug candidates provided b...
2020-01-01 | Financiado
TRIC-TB: Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments. BIOVERSYS AG tramitó un H2020: Tuberculosis (TB) is the world’s leading infectious disease. It killed 1.7 million people in 2016 and 10.4 million people developed active TB in the same year. In 2016, 480’000 of TB cases were multid...
2019-05-01 | Financiado
LYMPHVECs: Development of lipid nanoparticles based on solid matrix for Benznidazole oral delivery targeting to the lymphatic system to treat Chagas disease GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO tramitó un H2020: According to the WHO there are 8 million persons chronically infected by Chagas disease (CD) resulting in 12.000 reported deaths annually. CD is one of the most significant health problems of Latin Am...
2019-03-01 | Financiado
I-CONSENT: Improving the guidelines for Informed Consent, including vulnerable populations, under a gender perspective Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana tramitó un H2020: The informed consent (IC) process allows the subject to voluntarily decide whether or not his/her participation in research. Generally, ICs are difficult to read documents that do not include all stak...
2017-05-01 | Financiado
anTBiotic: AnTBiotic – progressing TB drug candidates to clinical proof of concept GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO tramitó un H2020: Tuberculosis (TB) today rivals HIV/AIDS as the leading cause of death from infectious diseases. The number of TB patients has never been higher and the growing proportion of drug-resistant TB is threa...
2017-01-01 | Financiado
COOPERA-TB: Hit to lead optimisation of novel anti-TB scaffolds through an academic-industrial partnership THE UNIVERSITY OF BIRMINGHAM tramitó un FP7: We propose a PhD programme for 4 Early-Stage Researchers (ESR) in tuberculosis (TB) drug discovery. Often associated with poverty, TB is rampant in many parts of Africa and Asia but has now also retur...
2014-02-01 | Financiado
NAREB: Nanotherapeutics for antibiotic resistant emerging bacterial pathogens INSTITUT PASTEUR tramitó un FP7: Increase in antibiotic resistance is a global concern worldwide. The project NAREBs main objective is the optimization of several nanoformulations of antibacterial therapeutics in order to improve the...
2014-02-01 | Financiado
OPENMEDCHEM: Medicinal Chemistry Open Innovation Doctorates UNIVERSITEIT ANTWERPEN tramitó un FP7: The establishment of influential public and private public partnerships fostering true collaboration between big Pharma and universities for a non-profit end goal has opened the door for stronger inte...
2012-10-01 | Financiado
PARAMET: A systematic analysis of parasite metabolism - from metabolism to intervention UNIVERSITY OF GLASGOW tramitó un FP7: Parasites exact a devastating toll on health and economic productivity, infecting man and also domestic livestock. Drugs used to combat parasitic diseases are deficient in many ways and new, better d...
2012-06-01 | Financiado
PREDICT-TB: Model-based preclinical development of anti-tuberculosis drug combinations GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO tramitó un FP6: Drug development in TB requires new integrated methods to transition the novel combination regimens needed to shorten first-line therapy and combat multi-drug resistance. Although new agents are emerg...
2012-05-01 | Financiado
FISHFORPHARMA: Training Network on Zebrafish Infection Models for Pharmaceutical Screens UNIVERSITEIT LEIDEN tramitó un FP7: Infectious diseases caused by pathogenic micro-organisms are major causes of death, disability, and social and economic disruption for millions of people. During evolution these pathogens have develop...
2012-01-01 | Financiado
UPSTREAM: European Research Training in the Ubiquitin Proteasome System ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE tramitó un FP7: The main objective of the international training network UPStream is the training of a novel generation of European scientist in a critical and complex field of modern biology: the understanding of th...
2011-11-01 | Financiado
ORCHID: Open Collaborative Model for Tuberculosis Lead Optimisation GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO tramitó un FP7: Early stage Drug Discovery efforts over the last 5 years have resulted in the identification of a number of promising lead compounds in the fight against TB. These leads need to be further progressed...
2011-01-01 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.